All Research Papers Published In ESMO Open

New
Research Article
10.1016/j.esmoop.2026.106085

Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma

Mar 1, 2026
ESMO Open
A.d Colevas + 19 more

New
Research Article
10.1016/j.esmoop.2026.106090

Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.

Mar 1, 2026
ESMO open
K Shitara + 19 more

New
Research Article
10.1016/j.esmoop.2025.106043

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

Mar 1, 2026
ESMO open
T Macarulla + 19 more

New
Research Article
10.1016/j.esmoop.2026.106066

Neoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric cancer: a meta-analysis.

Mar 1, 2026
ESMO open
W K Schwengber + 10 more

New
Research Article
10.1016/j.esmoop.2026.106088

Quality-of-life outcomes with pimitespib in patients with advanced gastrointestinal stromal tumor: results from the randomized, double-blind, placebo-controlled, phase III, CHAPTER-GIST-301 study

Mar 1, 2026
ESMO Open
Y Komatsu + 11 more

New
Research Article
10.1016/j.esmoop.2026.106084

Prognostic impact of pathological complete response and response-adapted outcomes in patients with gastroesophageal adenocarcinoma treated with neoadjuvant or perioperative treatments: a multicentric cohort study.

Mar 1, 2026
ESMO open
M Airoldi + 32 more

New
Research Article
10.1016/j.esmoop.2026.106087

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

Mar 1, 2026
ESMO open
L Paracchini + 22 more

New
Research Article
10.1016/j.esmoop.2026.106083

Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET.

Mar 1, 2026
ESMO open
J Hadoux + 24 more

New
Research Article
10.1016/j.esmoop.2026.106076

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors.

Mar 1, 2026
ESMO open
E.s.m Van Aken + 30 more

New
Research Article
10.1016/j.esmoop.2026.106089

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.

Mar 1, 2026
ESMO open
J Bedke + 9 more